Lannett Company, Inc. (NYSE:LCI)

CAPS Rating: 3 out of 5

The Company develops, manufactures, markets and distributes generic versions of pharmaceutical products.

Results 1 - 20 of 21 : 1 2 Next »

Recs

0
Member Avatar jsnms (20.37) Submitted: 7/31/2015 2:23:39 PM : Outperform Start Price: $59.79 LCI Score: -0.58

Great fundamentals. Look at stats and balance sheet.

Recs

3
Member Avatar XMFSeeker (68.38) Submitted: 1/29/2015 2:12:15 PM : Outperform Start Price: $49.53 LCI Score: +13.88

Lannett Company manufactures and distributes generic pharmaceutical products in tablets, capsule and oral liquid forms. The company has more than 40 marketed products across several therapeutic areas, but is strategically targeting its capabilities in controlled substances to drive its growth. Getting exclusive licenses is one important advantage that sets Lannet apart from other generic companies. For instance, it is an exclusive distributor of the Levothyroxine Tablets, one of the most prescribed drugs in the U.S. as well as being one of 7 companies named by the Drug Enforcement Administration with the ability to import concentrated opium straws, used in pain management. Having limited competition from other generic drug makers allows Lannett to enjoy a 70% gross margin and an impressive compound annual growth rate of 22% in the last 12 years. It also consistently generates a remarkable return on equity of 40% and has a levered free cash flow margin of 11%. Furthermore, here are two reasons why I think now is a great time to invest in Lannett. First, the company is only trading at a 17x earnings multiple and a PEG ratio of 0.2, low compared to the industry P/E average of 95x. And secondly, Lannett currently has 21 Abbreviated New Drug Applications in its pipeline, a robust number relative to its market value of $1.6 billion. A rapidly aging population, coupled with increasing prevalence of chronic illness and growing pressure from insurance firms to cut healthcare costs, Lannett is set to benefit. That’s why I believe Lannett has great growth potential.

Recs

0
Member Avatar Reddragyn (68.29) Submitted: 1/24/2015 2:41:42 AM : Outperform Start Price: $47.23 LCI Score: +21.03

Mag Inv Plus

Recs

0
Member Avatar 1badbeerad (34.55) Submitted: 1/18/2015 1:06:59 AM : Outperform Start Price: $45.29 LCI Score: +24.26

Nicely positioned generic drug maker.

Recs

0
Member Avatar griderX (96.78) Submitted: 8/20/2014 3:52:22 PM : Outperform Start Price: $36.84 LCI Score: +50.77

Taking advantage of short term price inflation on generics. I don't foresee this as sustainable, thus short term outperform...looking for a pop.

Recs

1
Member Avatar GAGA (< 20) Submitted: 2/5/2014 11:49:45 AM : Outperform Start Price: $36.23 LCI Score: +46.72

OBAMA CARE

Recs

0
Member Avatar Coreylan (25.62) Submitted: 12/26/2013 11:33:38 PM : Outperform Start Price: $36.23 LCI Score: +46.72

Affordable Care Act

Recs

1
Member Avatar tomi1970 (< 20) Submitted: 11/6/2013 10:22:00 PM : Underperform Start Price: $24.40 LCI Score: -114.30

cannot justify value at 23, see it at 9

Recs

0
Member Avatar gunterle (66.26) Submitted: 4/10/2013 2:04:53 PM : Outperform Start Price: $10.61 LCI Score: +391.05

signal

Recs

0
Member Avatar xaneti (62.87) Submitted: 1/18/2013 5:52:53 PM : Outperform Start Price: $5.90 LCI Score: +791.54

charles schwab screener A+ Pharma Generic low PEG < 1

Recs

0
Member Avatar worknhard (< 20) Submitted: 1/30/2012 10:30:15 AM : Outperform Start Price: $4.89 LCI Score: +963.94

FDA approvals opened up after 483's were fixed.
Backlog of approvals to come
Cody labs starting to hit stride and provide profits.

Recs

0
Member Avatar maniacdog (41.47) Submitted: 6/21/2011 10:14:22 AM : Outperform Start Price: $5.28 LCI Score: +880.88

Looks like morphine sulfate is the rage.

Recs

0
Member Avatar stktrdr1 (< 20) Submitted: 11/6/2010 10:34:17 PM : Outperform Start Price: $6.25 LCI Score: +712.36

LCI seems to have plans for new products and marketing they look as if they will do well over the next few months holding their own while the market makes the necessasry corrections.

Recs

1
Member Avatar meberlein (< 20) Submitted: 8/3/2009 8:36:11 AM : Outperform Start Price: $8.64 LCI Score: +434.77

The stock has been on the rise as of late and is doing so on the back of solid financials. The company in the past five years has had a top out in the low twenties with similiar data to what it is displaying currently. 200% increase within the next 1-2 years.

Recs

0
Member Avatar VoodooEconomist (47.51) Submitted: 4/14/2009 3:21:30 PM : Underperform Start Price: $5.79 LCI Score: -708.85

Correction only

Recs

1
Member Avatar FinancialModeler (26.44) Submitted: 3/11/2009 4:08:43 PM : Underperform Start Price: $5.30 LCI Score: -755.89

Whoever said this stock is under valued needs to learn what value really is. LCI has a PE ratio over 100. The stock trades within 10% of its 52 week high. Returns on assets, equity, and capital is almost nothing. No dividend. Less than 2% profit margin is weak. This is not value.

I want to see this stock drop down to $3 per share before I close this out.

Recs

0
Member Avatar meetme25 (57.17) Submitted: 10/11/2007 12:20:00 AM : Outperform Start Price: $4.63 LCI Score: +1,045.52

Insider buys

Recs

0
Member Avatar obiwankenobe1250 (89.04) Submitted: 12/10/2006 9:01:16 PM : Outperform Start Price: $6.69 LCI Score: +668.04

Great business in a growth industry. Fundamentals look real solid.

Recs

0
Member Avatar workinharder (< 20) Submitted: 12/7/2006 10:25:01 PM : Outperform Start Price: $6.66 LCI Score: +671.37

New facilities, managment team refocused, many applications awaiting approval.

Recs

0
Member Avatar RandyWill (96.68) Submitted: 11/26/2006 2:02:03 PM : Outperform Start Price: $7.00 LCI Score: +630.79

Seems underpriced given earnings projected by the lone analyst. Haven't had time to really dig into it though.

Results 1 - 20 of 21 : 1 2 Next »

Featured Broker Partners